NeuroPace Reports Strong Q1 2026 Results with Improved Margins and Reduced Cash Burn, Supporting Raised Guidance

summarizeSummary

NeuroPace reported strong Q1 2026 financial results, featuring improved gross margins and reduced cash burn from operations, despite a slight revenue dip due to the strategic termination of a distribution agreement. The company maintains adequate liquidity and is advancing its RNS System pipeline.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Revenue was $22.1 million, a 2% decrease year-over-year primarily due to the termination of the DIXI Medical distribution agreement, but core RNS System unit sales increased. Gross profit rose 4% to $18.0 million, with gross margin improving from 77.0% to 81.8%.

• Improved Operational Cash Flow

  Net cash used in operating activities decreased to $5.9 million for Q1 2026, compared to $7.5 million in Q1 2025, indicating improved cash management.

• Strategic Exit from DIXI Distribution

  The termination of the lower-margin DIXI Medical distribution agreement (completed December 31, 2025) positively impacted gross margin and allows the company to focus on its core RNS System.

• Adequate Liquidity and Debt Compliance

  As of March 31, 2026, the company had $54.0 million in cash, cash equivalents, and short-term investments, which management believes is sufficient for at least the next 12 months. NeuroPace is in compliance with all covenants of its MidCap Credit Agreement.

auto_awesomeAnalysis

NeuroPace's Q1 2026 results demonstrate solid operational improvements, particularly in profitability and cash management. While overall revenue saw a slight decrease due to the strategic exit from the lower-margin DIXI Medical distribution agreement, core RNS System sales increased, and gross margin significantly improved. The company's liquidity remains strong, providing sufficient runway for operations and continued investment in its RNS System, including pending label expansion efforts. This detailed report substantiates the positive Q1 performance and raised full-year guidance previously announced in an 8-K filing on the same day.